The Asia-Pacific with an intermediate to high prevalence, represents three-quarters of chronic hepatitis B (CHB)-positive subjects worldwide.
Novotech Publishes Multi-Specific Monoclonal Antibodies Global Clinical Trial Landscape Report
Singapore - Novotech, the leading Asia Pacific centred biotech CRO has published
Read more